Medication Treatment Guidelines for Substance Use Disorders (SUDs) - Buprenorphine Containing Products

Medical policy no. 65.20.00.10-1  Effective: September 11, 2018

Related medical policies:
- Medication Treatment Guidelines for Substance Use Disorders (SUDs) – Naltrexone Containing Products

Background:
Substance use disorders (SUDs) impacts the lives of millions of Americans in the general population, including individuals who are enrolled in the Medicaid program. The use of medications in combination with behavioral therapies to treat SUDs can help reestablish normal brain functioning, reduce cravings and prevent relapse. Multiple studies demonstrate that medications, opioid agonists and in some cases opioid antagonists are the most effective treatment for opioid use disorders. The medications used can manage the symptoms of substance use withdrawal that often prompt relapse and allow individuals to utilize other treatments, such as behavior therapy.

Medical necessity

<table>
<thead>
<tr>
<th>Medication Treatment for Substance Use Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>It is the goal of the Washington State Health Care Authority (HCA) to maximize opportunities for patients to receive effective and successful treatment for SUDs. Coverage of medications FDA approved or those that are listed as an approved indication in a pharmacologic compendia to treat SUDs increases the number of access points for treatment and provides patients with additional flexibility in managing their recovery.</td>
</tr>
</tbody>
</table>

HCA and its contracted Managed Care Organizations (MCO) will consider medications for the treatment of SUDs medically necessary whether prescribed in an outpatient, emergency room or hospital setting. (The meds may also be started in a hospital).

Clinical guidelines:

<table>
<thead>
<tr>
<th>Buprenorphine Containing Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buprenorphine containing products reduce or eliminate opioid withdrawal symptoms and opioid cravings. Because buprenorphine is a partial agonist, a partial receptor activator, the risk of overdose is less than with a full agonist like methadone. It is available for sublingual, buccal, subcutaneous injection and as an intradermal implant. Many formulations are combined with naloxone in an effort to deter diversion or abuse of the medication by causing a withdrawal reaction if it is intravenously injected by individuals dependent on opioids.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Buprenorphine monotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buprenorphine monotherapy requires prior authorization and is considered only for clients who are pregnant or those who have experienced a witnessed serious allergic reaction to the combined product, urticaria, angioedema or anaphylaxis, and meet DSM 5 criteria for moderate or severe opioid use disorder up to maximum dose limit of 32mg per day.</td>
</tr>
</tbody>
</table>
After delivery, patients must be transitioned to a buprenorphine/naloxone combination product.

For pregnant clients only: to allow a 7-day supply while the prior authorization is being processed an expedited authorization code 8500000077 may be used one time.

**Buprenorphine/Naloxone**

Buprenorphine/naloxone is covered up to dosing limits (see below) without authorization for all individuals who meet DSM-IV criteria for opioid dependence or DSM 5 criteria for moderate or severe opioid use disorder.


- If significant deviations from these guidelines occur, documentation in the patient record must support the medical necessity of the differences.

- Dose limits for buprenorphine/naloxone products
  - Bunavil: 16.8 mg/2.8 mg per day
  - Suboxone/generic: 32 mg/8 mg per day
  - Zubsolv: 22.8 mg/5.6 mg per day

**Medication Treatment for OUD:**

*Guidelines:*

- Any provider with a SAMHSA approved waiver may prescribe sublingual buprenorphine or buprenorphine/naloxone to anyone that meets the DSM criteria as listed above. Recognizing that there are children and adolescents with OUDs whose age is below that listed in the FDA product labelling, providers are encouraged to determine the risks and benefits of providing buprenorphine vs the risks and benefits of not providing medication treatment to persons less than 16 years of age with a OUD. Guidelines from the American Academy of Pediatrics support the use of medication for the treatment of opioid use disorder in children and adolescents.

- Given the importance of opioid substitution therapy to treatment success, and the need to reduce the risk of opioid overdose, enrollment in a DSHS approved treatment facility is not a requirement for initiating medication treatment with buprenorphine.

- Recognizing the chronic nature of opioid addiction, additional interventions that address the mental health and social needs of the patient should be considered. Patients who are unable to achieve a reduction in their use of illicit opioids and improve their functional status without engaging in a formal treatment program should be referred to a higher level of care.
• The Washington Prescription Monitoring Program must be accessed and reviewed for each patient before and at the time of induction.

Documentation Requirements:

Initiation of Medications to Treat OUD:
• A complete medical history, including information detailing the patient’s current and past history of drug or alcohol dependency and treatment, as well as any current or past history of mental health diagnosis and treatment, overdose or suicide attempt is required.
• Patients with a history of a prior overdose or suicide attempt are at increased risk for recurrence. Care for these patients should include discussing suicide and overdose safety plans and the danger of fentanyl. This group of patients ideally should also be prescribed naloxone and given information about the National Suicide Prevention Lifeline 1-800-273-8255 or the 24 hour crisis line number 1-866-427-4747.
• A physical exam appropriate to the patient’s clinical presentation and method of use should be documented.

First Six (6) Months:
• Point of care (POC), urine drug screens and/or random call backs of patients requesting they return to the clinic within a specified time frame with their remaining medications for a pill count must be conducted at least every month during the first six (6) months for patients new to buprenorphine or more often at the discretion of the provider.
• POC urine drug screens must include testing for buprenorphine, methadone, oxycodone benzodiazepines, Amphetamine/Methamphetamine, Cocaine and other opiates. (It is recognized that most POC urine drug screens do not test for all of the most commonly used benzodiazepines.) Testing for Barbiturates, THC and other substances should be guided by medical necessity. Documentation should support the request for testing of additional substances. Serial quantitative testing is not considered medically necessary and will not be covered. See (billing guide) for limits on urine drug screen testing.
• The Prescription Monitoring Program database must be checked at three (3) month intervals for the first six (6) months and then at the provider’s discretion but no less frequently than every six (6) months for patients receiving ongoing maintenance treatment.

After Six (6) Months:
After the first six (6) months of treatment and every six (6) months thereafter:
• POC urine drug screens and/or pill counts can be performed at the discretion of the provider but must occur no less often than every six (6) months.
• After six (6) months, if the patient is stable, the PMP must be checked at a minimum of every six (6) months.
• Screenings for depression and anxiety must be performed twice a year and documented in the patient’s chart, unless the patient is receiving treatment for either of these conditions in which case they should be repeated at the discretion of the provider.

Initial Prescription Requirements:
• Patients may not receive more than a seven (7) day supply of medication at the time of induction.
• An order for a urine drug screen is not required with the initial request for buprenorphine prior to initiating treatment but POC urine drug screens must be performed during the first month of treatment.
• Patients with significant untreated psychiatric comorbidity or those with a comorbid dependence on high dose benzodiazepines or other CNS depressants should be co-managed with an Addiction Medicine physician or a prescribing mental health provider where and if those resources are available. If these resources are not available, the risk of overdose with buprenorphine when combined with sedative-
hypnotics is much less than when they are combined with full agonists. Concurrent use of benzodiazepines is not a contra-indication to therapy with buprenorphine. When prescribing buprenorphine monotherapy or doses in excess of 32 mg per day, providers are required to obtain prior authorization by submitting Form 13-330 Medication Assisted Treatment Request for buprenorphine Monotherapy or Form 13-332 Medication Assisted Treatment Request for buprenorphine > 32 mg per day. These forms can be found on FFS Drug Coverage Criteria at http://www.hca.wa.gov/billers-providers/programs-and-services/apple-health-medicaid-drug-coverage-criteria. Directions for submitting request forms via the patient’s pharmacy can be found on the back of these forms.

Follow-Up Requirements in the First Six (6) Months:

- Patients are required to be seen within one (1) week of starting buprenorphine and then weekly for the first four (4) weeks of treatment. For physicians and patients in rural areas where there is not ready access to transportation, the week 3 and week 4 visit may be conducted by phone. A fourteen (14) day supply of medication may be prescribed in these instances. These phone visits must be scheduled at the time of the 2 week visit. The need and indication for conducting phone visits to replace in person visits must be clearly documented in the medical record. Telephone visits are not a reimbursable service.
- A POC urine drug screen documenting the buprenorphine is being taken should be collected during the first month of treatment.
- In addition to buprenorphine treatment, prescribing providers ideally should provide brief intervention and motivational interviewing techniques to help the patient identify and set self-management goals that promote their stabilization. Visiting in the primary care setting with the provider, mental health professional or care team coordinator are all acceptable types of follow up. If follow up visits are not with the prescribing practitioner, the prescriber must assure visits occurred and are clearly documented in the patient’s chart.
- The frequency of follow up visits after the first month should be a shared decision between the patient and the provider but must occur at least monthly.
- For non-pregnant patients reporting allergies to buprenorphine/naloxone and requesting a buprenorphine monotherapy, clinical documentation of witnessed hives, angioedema or anaphylaxis must be provided at the time of the request.
- Buprenorphine as a monotherapy will only be approved for dispensing in seven (7) day supplies until the patient demonstrates evidence of stability. Up to 14 days can be prescribed after the 2nd month if clinically stable. If travel burden or other circumstances limit the patient’s ability to come every 2 weeks, an exception requesting a longer duration can be made to the Health Care Authority.
- Buprenorphine monotherapy for pregnant patients with a history of a prior overdose or suicide attempt are at a high risk for overdose. These and other questions should be used to is limited to a maximum of a seven (7) day supply with a minimum follow up visit frequency as detailed in chart below. A buprenorphine/naloxone combination product should be started after delivery.
- For buprenorphine/naloxone treatment after induction and stabilization, no sooner than three (3) months, up to a 30-day supply of buprenorphine with refills may be prescribed at the physician’s discretion if patients are doing well. Visits after month 1 may occur at 2-4 week intervals. See table below for minimum required visit frequency and dosing limits for the first three (3) months:
### Visit Type | Follow-Up Interval | Medications dispensed (maximum of 32mg/day without authorization)
--- | --- | ---
Induction | Within 7 days | Maximum 7 days
Weeks 2 through 4 | Weekly visits | Maximum 7 days (see note above regarding rural areas)
Weeks 5 through 8 | Visits every 2 to 4 weeks | Maximum 14 days
Week 9 and beyond | Visits at providers discretion (see note above regarding rural areas) | 14-30 day supply

**PRESCRIBER INFORMATION:**

**PHARMACY INFORMATION:**
For Apple Health FFS clients: To submit a request for the buprenorphine mono-product or for daily doses of buprenorphine/naloxone exceeding dose limits (see below) you must:
- Complete the Pharmacy Information Authorization (13-835A) from as you would for any other authorization request.
- As supporting documentation to the Pharmacy Information Authorization (13-835A), attach the Medication Treatment Request form (13-330, 13-331, 13-332) completed by the prescriber.
- Fax both documents to HCA at (866) 668-1214. The Pharmacy Information Authorization 13-835A must be the first document in the fax transmission.
- Authorization request will not be reviewed until all necessary documents are received by the agency. Please be proactive in obtaining completed forms prior to requesting authorization.
- Patients who become pregnant and require a switch to the buprenorphine mono-product but do not have written confirmation in hand when presenting to the pharmacy can be dispensed an initial 3 day supply until verification can be obtained.

For Apple Health MCO clients: Refer to the MCO plan

**ADDITIONAL INFORMATION:**
- Patients may remain on medication treatments for OUD for as long as they are stable and demonstrate clinical improvement. Because patients differ in terms of their preferences and ability to manage their substance use disorder, the length of treatment should be determined by medical necessity.
- Patients who remain unstable and demonstrate continued use of other illicit drugs after stabilization on buprenorphine, should receive additional and/or increased intensity of services to achieve abstinence from illicit drugs. If on site services do not exist to meet the need for higher intensity services, patients should be referred to a licensed Opioid Treatment Program (OTP), a Chemical Dependency Professional or to an Addiction Medicine physician for evaluation and determination of the appropriate ASAM level of treatment placement.
Patients should be maintained on the dose necessary to achieve a reduction of their symptoms and abstinence or a reduction in their use of opioids. It is recognized that some patients may require doses above 16 mg to achieve this state. Requests for doses greater than dose limits require prior authorization.

Recognizing that certain groups of patients are at a higher risk of overdose than others (e.g. people who have co-existing serious mental illness or those who may be homeless) clinical strategies that allow same day or near same day access to buprenorphine induction with minimal barriers for patients are encouraged.

The prescribing physician should closely monitor use of other opioids or controlled substances while being treated with buprenorphine. Patients must consult with and receive approval from their buprenorphine prescriber for any medically necessary use of other opioids during the course of their treatment.

There is no lifetime limit on the duration of buprenorphine treatment.

Individual patients may not go through more than three (3) buprenorphine inductions in a calendar year, without consultation from an Addiction Medicine physician or referral to an OTP.


It is also recognized that patients with severe OUD may need to be seen daily or several times a week during induction and stabilization. Pharmacies are allowed to bill multiple fills for the 1st month of treatment.

For questions regarding this clinical policy, please contact:
- Charissa Fotinos, MD at [charissa.fotinos@hca.wa.gov](mailto:charissa.fotinos@hca.wa.gov)

### Monitoring for Compliance:
- Full record reviews may be requested by HCA or MCO staff if there are concerns regarding the appropriateness of continued buprenorphine treatment in a particular patient.
- Representatives of HCA or the patient’s MCO will also periodically review records of patients in the Prescription Monitoring Program to assure they are not receiving additional opioids or other types of controlled substances from other providers.

### Payment for Buprenorphine will be stopped if:
- Patient is found to be diverting some or all of their buprenorphine
- Patient is found to be selling their buprenorphine to others.

### Dosage and quantity limits

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dose Limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>buprenorphine monotherapy</td>
<td>32 mg per day</td>
</tr>
<tr>
<td>buprenorphine/naloxone</td>
<td>32 mg per day</td>
</tr>
<tr>
<td>Bunavail® buccal film</td>
<td>16.8 mg/2.8 mg per day</td>
</tr>
<tr>
<td>Suboxone® sublingual film</td>
<td>32 mg per day</td>
</tr>
<tr>
<td>Subutex® sublingual tablet</td>
<td>32 mg per day</td>
</tr>
<tr>
<td>Zubsolv® sublingual tablet</td>
<td>22.8 mg/5.6mg per day</td>
</tr>
</tbody>
</table>
References

1. AAP COMMITTEE ON SUBSTANCE USE AND PREVENTION.